AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$TWST

Leproust Emily M. sold $923K of TWST

Leproust Emily M. (Chief Executive Officer) sold 6,639 shares of Twist Bioscience Corp (TWST) at $139.07 ($0.92M total) on 2026-08-21.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Aug 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership, which may be interpreted as a bearish sign, but the modest size limits market reaction.

02

Market read

Primary relevance to Twist Bioscience (TWST) shareholders; limited broader market effect.

03

What to watch

CEO may be exercising pre-arranged tax planning; no 10b5-1 plan was used.

Relevance 5/10Novelty 5/10Timing: post-market 2026-08-21

Background

Form 4 filings disclose insider transactions; investors monitor them for cues on insider confidence.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

CEO Emily Leproust sold 6,639 shares for $923,259, reducing her stake to 812,299 shares.

Expected impact

Possible short-term dip as market digests insider sell.

Evidence & confidence

The sale size is modest relative to market cap but involves the CEO, which can influence sentiment.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and not sector-wide.

Regional

No regional effect; confined to Twist Bioscience shareholders.

Global

Limited global relevance; only affects TWST investors.

Counterpoint

What could challenge this read

The sale could be a routine diversification, not a negative signal.

Key entities

  • person
    Emily M. Leproust

    Chief Executive Officer of Twist Bioscience

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min